Who is eligible for clinical trial NCT06981078?

Participants must meet protocol criteria for Chronic Obstructive Pulmonary Disease. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT06981078 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-07-17

A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD (NCT06981078)

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Upstream Bio Inc.

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to assess the efficacy and safety of verekitug (UPB-101) in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), an inflammatory lung disease.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (6 items) and avoid the listed exclusions (9 items).

Location: Kern Research Inc. — Bakersfield, California

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Physician diagnosis of COPD for \>12 months.
Current or former smokers with a smoking history of 10 pack-years or more.
Post-bronchodilator FEV1/ Forced Vital Capacity (FVC) ratio \<0.70 and predicted post-bronchodilator FEV1 \>30% and ≤80%.
Modified Medical Research Council dyspnea scale Grade ≥2.
Background triple therapy (Inhaled Corticosteroid \[ICS\], Long-Acting Beta Agonist \[LABA\], Long-Acting Muscarinic Antagonist \[LAMA\]) for 3 months before randomization with a stable dose of medications for 1 or more months prior to Visit 1.
Are ≥80% compliant with background therapy during the screening period.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Moderate or severe exacerbation of COPD within 4 weeks prior to or during the screening period.
Respiratory tract infection within 4 weeks prior to or during the screening period.
Treatment with oxygen of \>4 liters/minute. Nocturnal oxygen use for sleep apnea is allowed.
Systemic or biologic immunosuppressant therapy to treat inflammatory disease or autoimmune disease within 24 weeks or 5 half-lives prior to Visit 1, whichever is longer, with the exception of oral corticosteroids. Treatment with cyclophosphamide and rituximab within 12 months of Visit 1.
Current diagnosis of asthma according to the 2023 Global Initiative for Asthma guidelines or other accepted guidelines
History or evidence of a clinically meaningful pulmonary condition other than COPD (e.g., pulmonary fibrosis, sarcoidosis, interstitial lung disease, pulmonary hypertension, bronchiectasis, Churg-Strauss Syndrome) or another diagnosed pulmonary or systemic disease associated with elevated peripheral eosinophil counts.
Chronic hypercapnia requiring Bilevel Positive Airway Pressure (BiPAP). Participants requiring BiPAP periodically for an acute COPD exacerbation are not excluded.
Any of the following in the previous 6 months prior to Visit 1: acute myocardial infarction, transient ischemic attack or stroke, hospitalization for any cardiovascular or cerebrovascular event, pulmonary embolism, deep vein thrombosis and cardiac arrhythmias including paroxysmal (e.g., intermittent). Participants with persistent atrial fibrillation as defined by continuous atrial fibrillation for at least 6 months and controlled with a rate control strategy (i.e., selective beta blocker, calcium channel blocker, pacemaker placement, digoxin or ablation therapy) and stable appropriate level of anticoagulation for at least 6 months may be considered for inclusion.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (242 Sites)

Kern Research Inc. — Bakersfield, California
PulmoCrit Associates — Encino, California
Torrance Clinical Research Institute — Lomita, California
Dream Team Clinical Research — Pomona, California
Apex Clinical Research — San Diego, California
Allianz Research Institute — Westminster, California
D&H Doral Research Center, LLC — Doral, Florida
Qway Research, LLC — Hialeah, Florida
Finlay Medical Research — Miami, Florida
MplusM - ITB Research — Miami, Florida
Florida Institute for Clinical Research,LLC — Orlando, Florida
Velocity Clinical Research-Savannah - Internal Medicine — Savannah, Georgia
Christie Clinic, LLC — Champaign, Illinois
Velocity Clinical Research-Rockville — Rockville, Maryland
Chesapeake Clinical Research, Inc — White Marsh, Maryland
HealthPartners — Saint Paul, Minnesota
American Health Research, Inc. — Charlotte, North Carolina
Velocity Clinical Research, Anderson — Anderson, South Carolina
SleepMed Inc. — Columbia, South Carolina
Velocity Clinical Research, Gaffney — Greenville, South Carolina
Velocity Clinical Research, Spartanburg - Pulmonology — Spartanburg, South Carolina
Velocity Clinical Research- Union — Union, South Carolina
El Paso Pulmonary Association — El Paso, Texas
Victorium Clinical Research — Houston, Texas
Synergy Groups Medical LLC — Houston, Texas

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗